机构:[1]Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, 6 Tiantan Xili, Dongcheng District, Beijing 100050, China重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院[2]Department of Neurosurgery, Qingdao Huangdao district People’s Hospital, Qingdao 266400, Shandong, China[3]Department of Neurotrauma, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China研究所北京市神经外科研究所首都医科大学附属天坛医院[4]Nerve Injury and Repair Center of Beijing Institute for Brain Disorders, Beijing 100050, China[5]China National Clinical Research Center for Neurological Diseases, Beijing 100050, China[6]Beijing Key Laboratory of Central Nervous System Injury, Beijing 100050, China
Secretory meningioma (SM) is a rare histological subtype of the meningioma family. Few reports investigating SM have been published due to its extremely low incidence; thus, the current understanding of this disease is poor. We analyzed the incidence and clinical, radiological, pathological, and prognostic features of SM. Approximately 12,380 intracranial meningiomas were surgically resected at Beijing Tiantan Hospital between April 2008 and January 2017. All pathologically confirmed SM cases were identified. SMs accounted for approximately 1.2% of the intracranial meningiomas (149 of 12,380). The patients with SM had a mean age of 51.0 years and were predominantly female (112 female and 37 male). Radiologically, peritumoral brain edema was observed in 49 (32.9%) patients. Gross total resection was achieved in 115 (77.2%) cases. At the 35-months median follow-up (range 4-109 months), six patients had tumor recurrence, and one patient died from the tumor recurrence. The 5-year progression-free survival rates were 95.9%, and the 5-year overall survival rate was 99.3%. A skull base location and a tumor size >= 3.5 cm were significantly associated with poor short-term outcomes, and a skull base location was significantly associated with an increased risk of poor long-term outcomes (P < 0.05). A skull base location (OR 3.797; 95% CI 1.071-13.468; P = 0.039) and tumor size >= 3.5 cm (OR 2.616; 95% CI 1.107-6.181; P = 0.028) were independent risk factors for non-gross total resection. A son-skull base location (OR 0.070; 95% CI 0.028-0.177; P = 0.001) was the only independent risk factor that correlated with more severe peritumoral brain edema. SM is a rare subtype of meningiomas with a female predominance and low recurrence. Our results highlight the risk factors for short- and long-term outcomes, which can be useful for selecting treatments and predicting prognosis. Microsurgical treatment of a skull base SM remains a formidable challenge due to a large tumor size and critical neurovascular structure encasement.
第一作者机构:[1]Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, 6 Tiantan Xili, Dongcheng District, Beijing 100050, China
通讯作者:
通讯机构:[1]Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, 6 Tiantan Xili, Dongcheng District, Beijing 100050, China[3]Department of Neurotrauma, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China[4]Nerve Injury and Repair Center of Beijing Institute for Brain Disorders, Beijing 100050, China[5]China National Clinical Research Center for Neurological Diseases, Beijing 100050, China[6]Beijing Key Laboratory of Central Nervous System Injury, Beijing 100050, China
推荐引用方式(GB/T 7714):
Tao Xiaogang,Wang Kun,Dong Jinqian,et al.Clinical features, surgical management, and prognostic factors of secretory meningiomas: a single-center case series of 149 patients[J].JOURNAL OF NEURO-ONCOLOGY.2018,136(3):515-522.doi:10.1007/s11060-017-2671-x.
APA:
Tao, Xiaogang,Wang, Kun,Dong, Jinqian,Hou, Zonggang,Wu, Zhen...&Liu, Baiyun.(2018).Clinical features, surgical management, and prognostic factors of secretory meningiomas: a single-center case series of 149 patients.JOURNAL OF NEURO-ONCOLOGY,136,(3)
MLA:
Tao, Xiaogang,et al."Clinical features, surgical management, and prognostic factors of secretory meningiomas: a single-center case series of 149 patients".JOURNAL OF NEURO-ONCOLOGY 136..3(2018):515-522